# Semaglutide for Weight Loss Philippines | Complete Guide Source: https://www.philippinespeptides.com/weightloss/semaglutide Updated: 2026-10-01 > Semaglutide for weight loss in the Philippines: what the phase 3 STEP trials measured, the side effects they reported, and Ozempic and Wegovy status. On this page - [Overview](#overview) - [Ozempic and Wegovy](#ozempic) - [What the trials found](#trials) - [Side effects reported](#side-effects) Weight Loss · Compound File # Semaglutide for weight loss Philippines Peptides editorial desk Updated 1 October 2026 3 min read **Compound** - Semaglutide **US FDA** - Approved (Ozempic, Wegovy) **STEP 1, phase 3** - 14.9% at 68 wk **STEP 1 mean weight lossPhase 3, 2.4 mg arm, against 2.4% on placebo** - 14.9% **STEP 1 duration** - 68wk **Class** - GLP-1 **US FDA** - Approved ## Overview Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It acts on the same receptor as the gut hormone GLP-1, which signals fullness and slows how quickly the stomach empties. It is studied and approved for type 2 diabetes and for chronic weight management, and its largest weight trials are the phase 3 STEP programme, summarised below with the side effects they reported. Two brands, one molecule ## Ozempic and Wegovy Semaglutide is the active ingredient in both Ozempic and Wegovy. Ozempic is indicated for type 2 diabetes; Wegovy is the weight-management brand, and the 2.4 mg arm studied in STEP 1 is the Wegovy dose. Both are prescription medicines. Ozempic is a prescription medicine in the Philippines, and prescribing belongs with a licensed Philippine physician. Whether it suits you, and at what dose, is a decision for that physician. The [semaglutide guide](https://www.philippinespeptides.com/peptides/semaglutide) covers what the trials of semaglutide measured and the side effects they reported. What Philippine law says about registration and prescriptions is in the [regulation hub](https://www.philippinespeptides.com/legal). Dated Philippine pharmacy prices for Ozempic are on the [semaglutide guide](https://www.philippinespeptides.com/peptides/semaglutide), and for Wegovy on the [Wegovy price page](https://www.philippinespeptides.com/guides/wegovy-price-philippines). Semaglutide is a prescription medicine in the Philippines and prescribing belongs with a licensed Philippine physician. Readers comparing this against the dual and triple agonists usually want the peso figures, which sit with our partner and supplier. [View Primara Labs pricing](https://www.primaralabs.com/marketplace?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline&utm_content=semaglutide) ## What the STEP trials found In STEP 1, a 68-week phase 3 trial of 1,961 adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes, body weight fell by 14.9% on the 2.4 mg arm, against 2.4% on placebo. [Source](https://doi.org/10.1056/NEJMoa2032183) What happens after stopping was measured in STEP 4, a 68-week phase 3 trial in which adults who reached semaglutide 2.4 mg during a 20-week run-in were randomised to continue or switch to placebo: body weight fell by 7.9% on continued treatment and rose by 6.9% after the switch to placebo. [Source](https://doi.org/10.1001/jama.2021.3224) Every STEP trial on file, with its population and comparator, is on the [semaglutide guide](https://www.philippinespeptides.com/peptides/semaglutide). ## Side effects reported STEP 5, a 104-week phase 3 trial of 304 adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, compared semaglutide 2.4 mg with placebo and reported these adverse events: - Discontinuation for adverse events: 5.9% on the 2.4 mg arm, against 4.6% on placebo. - Gastrointestinal adverse events: 82.2% on the 2.4 mg arm, against 53.9% on placebo. - Nausea: 53.3% on the 2.4 mg arm, against 21.7% on placebo. - Diarrhoea: 34.9% on the 2.4 mg arm, against 23.7% on placebo. - Constipation: 30.9% on the 2.4 mg arm, against 11.2% on placebo. - Vomiting: 30.3% on the 2.4 mg arm, against 4.6% on placebo. [Source](https://doi.org/10.1038/s41591-022-02026-4) The product labels also carry warnings for pancreatitis, gallbladder disease and thyroid C-cell tumours, the last seen in rodent studies. The [GLP-1 side effects guide](https://www.philippinespeptides.com/guides/glp1-side-effects) covers them in full. ↗ Related guides - [Full Semaglutide Guide](https://www.philippinespeptides.com/peptides/semaglutide) - [Compare: Tirzepatide](https://www.philippinespeptides.com/weightloss/tirzepatide) - [Compare: Retatrutide](https://www.philippinespeptides.com/guides/retatrutide-philippines-2026) - [View Supply Index](https://www.philippinespeptides.com/supply) Our partner and supplier ### What the newer agonists cost locally Primara Labs, our partner and supplier, lists tirzepatide 15mg at PHP 2,100 and retatrutide 20mg at PHP 3,775 as research vials, priced in pesos from stock inside the Philippines. These are research materials, not pharmacy products, and anything you intend to use belongs in a conversation with a licensed Philippine physician. Metro Manila dispatch is same day, the rest of the country 1 to 5 business days. --- Philippines Peptides sells nothing. Primara Labs is our partner and supplier. This is general information, not medical or legal advice.